Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Sznol

Showing results (51-60 of 188) with videos related to

Pageof 19
Sort By:
Laboratory Investigation; a Journal of Technical Methods and Pathology|July 16, 2008
Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cellsHarriet M Kluger, Summar F Siddiqui, Cesar Angeletti, et al.
Clinical Genitourinary Cancer|January 21, 2023
Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell CarcinomaNazli Dizman, Matthew Austin, Bryden Considine, et al.
Oncotarget|May 2, 2019
A novel anti-melanoma SRC-family kinase inhibitorRuth Halaban, Antonella Bacchiocchi, Robert Straub, et al.
Cancer Gene Therapy|September 23, 2003
Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patientsJohn Nemunaitis, Casey Cunningham, Neil Senzer, et al.
Cancer Treatment Reviews|July 10, 2017
Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their managementMario Sznol, Michael A Postow, Marianne J Davies, et al.
Leukemia Research|July 21, 2007
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disordersJudith E Karp, Francis J Giles, Ivana Gojo, et al.
Proceedings of the American Thoracic Society|May 3, 2012
Chitinase-like proteins in lung injury, repair, and metastasisChun Geun Lee, Charles S Dela Cruz, Bing Ma, et al.
Journal of Cancer Research and Clinical Oncology|August 23, 2018
Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysisHoward L Kaufman, Lawrence H Schwartz, William N William, et al.
Journal of Translational Medicine|January 30, 2007
The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitizationHarriet M Kluger, Mary M McCarthy, Ayesha B Alvero, et al.
Leukemia Research|February 28, 2007
Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignanciesIvana Gojo, Michael L Tidwell, Jacqueline Greer, et al.
Pageof 19

Showing results (51-60 of 188) with videos related to

Sort By:
Pageof 19
Laboratory Investigation; a Journal of Technical Methods and Pathology|July 16, 2008
Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cellsHarriet M Kluger, Summar F Siddiqui, Cesar Angeletti, et al.
Clinical Genitourinary Cancer|January 21, 2023
Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell CarcinomaNazli Dizman, Matthew Austin, Bryden Considine, et al.
Oncotarget|May 2, 2019
A novel anti-melanoma SRC-family kinase inhibitorRuth Halaban, Antonella Bacchiocchi, Robert Straub, et al.
Cancer Gene Therapy|September 23, 2003
Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patientsJohn Nemunaitis, Casey Cunningham, Neil Senzer, et al.
Cancer Treatment Reviews|July 10, 2017
Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their managementMario Sznol, Michael A Postow, Marianne J Davies, et al.
Leukemia Research|July 21, 2007
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disordersJudith E Karp, Francis J Giles, Ivana Gojo, et al.
Proceedings of the American Thoracic Society|May 3, 2012
Chitinase-like proteins in lung injury, repair, and metastasisChun Geun Lee, Charles S Dela Cruz, Bing Ma, et al.
Journal of Cancer Research and Clinical Oncology|August 23, 2018
Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysisHoward L Kaufman, Lawrence H Schwartz, William N William, et al.
Journal of Translational Medicine|January 30, 2007
The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitizationHarriet M Kluger, Mary M McCarthy, Ayesha B Alvero, et al.
Leukemia Research|February 28, 2007
Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignanciesIvana Gojo, Michael L Tidwell, Jacqueline Greer, et al.
Pageof 19